Bayer, Onyx Pharma Say Phase 3 Trial Of NEXAVAR Fails To Meet Primary Endpoint

July 25, 2014 7:19 AM

7 0

Bayer HealthCare Pharmaceuticals Inc., a subgroup of Bayer AG (BAYZF.PK,BAYRY.PK,BYR.L), and Onyx Pharmaceuticals Inc., an subsidiary of Amgen (AMGN: Quote), reported that an investigational Phase 3 study of NEXAVAR or sorafenib tablets in patients with advanced breast cancer failed to achieve its primary endpoint of improving progression-free survival or PFS.

The RESILIENCE (Phase 3 TRial Comparing CapecitabinE in Combination with SorafenIb or PLacebo for Treatment of Locally Advanced or MetastatIc HER2-Negative Breast CancEr) trial was a randomized, double-blind, placebo-controlled Phase III study which enrolled 537 patients in over 20 countries, includ...

Read more

To category page

Loading...